← FDA DRUG APPROVALS

FDA NDA · NDA050549

MEZLIN

Sponsor: BAYER PHARMS

APPLICATION
NDA050549
TYPE
NDA
ORIGINAL APPROVAL
1981-09-21
LATEST ACTION
1998-11-10
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

MEZLINDiscontinued
MEZLOCILLIN SODIUM MONOHYDRATE EQ 3GM BASE/VIAL · INJECTABLE · INJECTION
MEZLINDiscontinued
MEZLOCILLIN SODIUM MONOHYDRATE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
MEZLINDiscontinued
MEZLOCILLIN SODIUM MONOHYDRATE EQ 4GM BASE/VIAL · INJECTABLE · INJECTION
MEZLINDiscontinued
MEZLOCILLIN SODIUM MONOHYDRATE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
MEZLINDiscontinued
MEZLOCILLIN SODIUM MONOHYDRATE EQ 20GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

1998-11-10Labeling · Supplement 22 · standardAP
1997-08-05Labeling · Supplement 21 · standardAP
1996-12-26Labeling · Supplement 20 · standardAP
1981-09-21Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →